Abstract
Although trazodone is approved and marketed in most countries worldwide for the sole treatment of Major Depressive Disorder, the use for this medication is very common for many other conditions, such as primary or secondary insomnia, Generalised Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and Obsessive- Compulsive Disorder. Other, not officially approved, uses of trazodone include: the treatment of bulimia, benzodiazepine and/or alcohol dependence or abuse, fibromyalgia, degenerative diseases of the central nervous system such as dementia and other organic disorders, schizophrenia, chronic pain, and diabetic neuropathy. In addition, due to its 5HT2A receptor antagonistic action, trazodone may be used to prevent the occurrence of initial and long-term side effects of SSRI, such as anxiety, insomnia and sexual dysfunction.
Despite the favorable clinical experience and the encouraging results from the studies that have tested the efficacy of trazodone for some of its off-label indications, it is paramount that large, randomized and controlled clinical trials be conducted in the near future to evaluate which of the many off-label indications are supported by a strong scientific evidence.
Keywords: Anxiety, insomnia, off label, SSRI combination, serotonergic, trazodone.
Current Pharmaceutical Design
Title:Off-Label Trazodone Prescription: Evidence, Benefits and Risks
Volume: 21 Issue: 23
Author(s): Letizia Bossini, Anna Coluccia, Ilaria Casolaro, Jim Benbow, Giovanni Amodeo, Riccardo De Giorgi and Andrea Fagiolini
Affiliation:
Keywords: Anxiety, insomnia, off label, SSRI combination, serotonergic, trazodone.
Abstract: Although trazodone is approved and marketed in most countries worldwide for the sole treatment of Major Depressive Disorder, the use for this medication is very common for many other conditions, such as primary or secondary insomnia, Generalised Anxiety Disorder, Panic Disorder, Post-Traumatic Stress Disorder and Obsessive- Compulsive Disorder. Other, not officially approved, uses of trazodone include: the treatment of bulimia, benzodiazepine and/or alcohol dependence or abuse, fibromyalgia, degenerative diseases of the central nervous system such as dementia and other organic disorders, schizophrenia, chronic pain, and diabetic neuropathy. In addition, due to its 5HT2A receptor antagonistic action, trazodone may be used to prevent the occurrence of initial and long-term side effects of SSRI, such as anxiety, insomnia and sexual dysfunction.
Despite the favorable clinical experience and the encouraging results from the studies that have tested the efficacy of trazodone for some of its off-label indications, it is paramount that large, randomized and controlled clinical trials be conducted in the near future to evaluate which of the many off-label indications are supported by a strong scientific evidence.
Export Options
About this article
Cite this article as:
Bossini Letizia, Coluccia Anna, Casolaro Ilaria, Benbow Jim, Amodeo Giovanni, De Giorgi Riccardo and Fagiolini Andrea, Off-Label Trazodone Prescription: Evidence, Benefits and Risks, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619092236
DOI https://dx.doi.org/10.2174/1381612821666150619092236 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antidiabetic Drugs as Antihypertensives: New Data on the Horizon
Current Vascular Pharmacology Vascular Endothelial Growth Factor Electro-Gene Therapy Improves Functional Outcome in a Mouse Model of ALS
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Perceptions in Type 1 Diabetes Mellitus with or Without the Use of Insulin Pump: An Online Study
Current Diabetes Reviews Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part I
Inflammation & Allergy - Drug Targets (Discontinued) The Oxido-reductase Activity of the Apoptosis Inducing Factor: A Promising Pharmacological Tool?
Current Pharmaceutical Design Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis
Current Vascular Pharmacology Plasma Glucose Lowering Activity of Palmatine and its Effect on Liver, Kidney and Antioxidant Enzymes Parameters in STZ Induced Diabetic Rat Model
Current Bioactive Compounds Atrial Fibrillation with a Focus on Oral Antiarrhythmic Therapy
Current Drug Therapy Role of Sulfur Containing Amino Acids as an Adjuvant Therapy in the Prevention of Diabetes and its Associated Complications
Current Diabetes Reviews Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry SiRNA Nanotherapeutics _The Panacea of Diseases?
Current Gene Therapy Commentary (Research Highlights: WNT-erizing Against Neuropathic Pain)
CNS & Neurological Disorders - Drug Targets Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design A PPAR-β/δ Agonist is Neuroprotective and Decreases Cognitive Impairment in a Rodent Model of Parkinson’s Disease
Current Neurovascular Research Oxidative Stress in the Pathogenesis/Treatment of Diabetes and its Complications
Current Nutrition & Food Science Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Current and Promising Therapies in Autosomal Recessive Ataxias
CNS & Neurological Disorders - Drug Targets Substance P in Rheumatic Diseases
Current Rheumatology Reviews